| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ACL; ATPCL; CLATP |
| WB Predicted band size | 121 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ACLY |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与ACLY抗体相关的参考文献，按发表时间排序：
1. **《ATP-citrate lyase links cellular metabolism to histone acetylation》**
- 作者：Wellen KE, et al.
- 摘要：该研究揭示了ACLY在连接细胞代谢与表观遗传调控中的关键作用，通过调控乙酰辅酶A水平影响组蛋白乙酰化。研究中采用ACLY抗体进行Western blot和免疫沉淀，验证了ACLY在代谢-表观遗传轴中的功能。
2. **《ATP citrate lyase inhibition can suppress tumor cell growth》**
- 作者：Hatzivassiliou G, et al.
- 摘要：文章报道了ACLY作为癌症治疗靶点的潜力，证明其抑制剂可抑制肿瘤细胞增殖。研究使用ACLY抗体通过免疫组化分析多种癌症组织中ACLY的过表达，并验证其在脂质合成通路中的关键地位。
3. **《ACLY ubiquitination by CUL3-KLHL25 induces energy production to promote brain tumorigenesis》**
- 作者：Cheng C, et al.
- 摘要：该研究阐明了ACLY在脑肿瘤发生中的调控机制，发现CUL3-KLHL25介导的泛素化修饰影响ACLY稳定性。通过ACLY抗体进行免疫共沉淀和蛋白质稳定性实验，揭示了ACLY代谢活性与肿瘤能量代谢的关联。
4. **《A common variant in ACLY promotes hepatic steatosis by regulating ATP citrate lyase stability》**
- 作者：Zhao S, et al.
- 摘要：研究通过人群遗传学分析发现ACLY基因变异与非酒精性脂肪肝相关，利用ACLY抗体进行肝组织Western blot和免疫荧光，证实变异体通过增强蛋白稳定性促进脂质蓄积。
注：以上摘要经过简化概括，实际文献需通过PMID或DOI在PubMed等平台查阅全文。
ACLY (ATP-citrate lyase) antibodies are essential tools for studying the enzyme ATP-citrate lyase, a key metabolic protein that catalyzes the conversion of citrate and coenzyme A into acetyl-CoA and oxaloacetate in the cytoplasm. This reaction bridges carbohydrate metabolism (via the tricarboxylic acid cycle) and lipid biosynthesis, making ACLY critical for fatty acid and cholesterol synthesis. ACLY is highly expressed in tissues with active lipogenesis, such as liver, adipose, and proliferating cells, and its dysregulation is linked to metabolic disorders, cancer, and cardiovascular diseases.
ACLY antibodies are widely used in research to detect ACLY expression levels, localization, and post-translational modifications (e.g., phosphorylation at Ser455) via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They help explore ACLY's role in cancer progression, where its upregulation supports tumor growth by fueling lipid synthesis, or in metabolic conditions like obesity and atherosclerosis. Additionally, ACLY is a therapeutic target, with inhibitors like Bempedoic acid (ETC-1002) approved for lowering LDL cholesterol. Antibodies thus aid in validating drug efficacy and mechanistic studies. Commercial ACLY antibodies are typically raised against peptide epitopes from conserved regions (human, mouse, rat), and validation includes knockout controls to ensure specificity. Their applications span basic research, biomarker discovery, and preclinical drug development.
×
